1. BMS, IMS, EMAS, RCOG and AMS joint statement on menopausal hormone therapy and breast cancer risk in response to EMA Pharmacovigilance Risk Assessment Committee recommendations in May 2020. Issue 1 (March 2021) Authors: Hamoda, Haitham; Davis, Susan R; Cano, Antonio; Morris, Edward; Davison, Sonia; Panay, Nicholas; Lumsden, Mary A; Hillard, Tim; Simoncini, Tommaso Journal: Post reproductive health Issue: Volume 27:Issue 1(2021) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗